Drug intelligence / Profile preview

BMC128

Development stage: Phase 1
Lead developer: Biomica
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

BMC128 is an investigational **microbiome-based live biotherapeutic product** being developed by Biomica for immuno-oncology. It is described as a consortium of selected microbial strains derived using Evogene's computational biology platform and is intended to modulate the intestinal microbiome to overcome resistance and enhance response to **nivolumab** in solid tumors. Public clinical-trial disclosures identify development in combination with nivolumab for patients with **non-small cell lung cancer, melanoma, and renal cell carcinoma**, with Phase 1 evaluation focused on safety and tolerability and company communications indicating plans to advance the program into Phase 2 and later out-license global development to Shanghai Lishan Biopharmaceuticals.

Beyond the preview

Go deeper on BMC128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMC128.

Explore the full profile